Boardroom Alpha
Boardroom Alpha
ISPC · Additional Proxy Materials (DEFA14A) · Filed May 18, 2026

Ispecimen Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 18, 2026
Ticker
ISPC
Accession
0001213900-26-058184
Boardroom Alpha · Filing insights

iSpecimen Inc. adjourns annual meeting to May 29, 2026; board urges voting FOR all proposals.

About Ispecimen Inc
Market cap
$4M
1Y TSR
−90.4%
3Y TSR
−84.5%
Board grade
D
Sector
Healthcare
CEO
Katharyn Field
Last annual meeting: Dec 31, 2025 · View full Ispecimen Inc profile →

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

SCHEDULE 14A INFORMATION

 

 

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

 

Filed by the Registrant  
Filed by a Party other than the Registrant  

 

Check the appropriate box:

 

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12

 

iSpecimen Inc.
(Name of Registrant as Specified in its Charter)

 

N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

PAYMENT OF FILING FEE (Check the appropriate box):

 

No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 

 

On May 18, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), is sending the following letter to stockholders in connection with the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The definitive proxy statement for the Annual Meeting was filed with the Securities and Exchange Commission on November 21, 2025.

 

***

 

2

 

 

May 18, 2026

 

Dear Fellow iSpecimen Stockholders,

 

Our Annual Meeting, originally scheduled for December 31, 2025, has been adjourned once again to May 29, 2026 at 9 am EST due to a lack of quorum. To date, we have not received your vote, so please take the time to cast your vote today and help us avoid further expenses associated with this meeting. The items on the ballot include the election of one director, Arphing (Tommy) Lee, for a 3-year term expiring at the 2028 annual meeting, ratification of Bush & Associates CPA LLC as our independent registered public accounting firm for the year ending December 31, 2025, approval of the iSpecimen Inc. 2025 Stock Incentive Plan, and transaction of such other business that may come before the meeting.

 

Your Board of Directors recommends that stockholders vote “FOR” all proposals outlined in the proxy materials previously provided to you.

 

Regardless of the number of shares you own, your vote is very important. Whether or not you plan to attend the meeting, we encourage you to vote as soon as possible to ensure that your shares are represented. Even if you have since sold your shares, you still have the right to vote as a holder of record on November 3, 2025.

 

Voting is quick and easy. You may vote by any of the following methods:

 

Online: www.proxyvote.com

 

Telephone: 800-454-8683

 

If you have already voted your shares, please accept our sincere thanks and disregard this reminder. If you have any questions or need assistance voting your shares, please call (877) 598-6925.

 

Thank you for your continued support and participation.

 

Sincerely,  
   
/s/ Katharyn Field  
Katharyn Field  
Chief Executive Officer  

 

 

3

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Ispecimen Inc (ISPC)

Reference

Frequently asked questions

When did Ispecimen Inc file this DEFA14A?
Ispecimen Inc (ISPC) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 18, 2026. The accession number assigned by EDGAR is 0001213900-26-058184.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
iSpecimen Inc. adjourns annual meeting to May 29, 2026; board urges voting FOR all proposals. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Ispecimen Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Ispecimen Inc has filed under CIK 1558569, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer